CLOs on the Move

COMPLEX SYSTEMS SOLUTIONS

www.csswa.com

 
COMPLEX SYSTEMS SOLUTIONS is a Richland, WA-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

LeaderOne Financial

LeaderOne Financial, or Leader1, is here for all your home buying and refinancing mortgage needs! Leader1 knows that youre a person. Youre also unique, an

ODC Network

The ODC Network is an outdoor education and conservation organization focused on connecting people, land, and nature. Since 2000, the ODC has served more than 500,000 children and adults through outdoor education and recreation programs. More than 75,000 people annually visit ODC Network sites to walk the trails and view the wildlife. With its partners, the organization helps protects over 1,200 acres along the Macatawa River and the Outdoor Discovery Center - a 155 acre nature preserve in Holland, MI. The ODC Nature Preserve is free and open to the public dawn to dusk every day of the year.

Conservation Services Group

Founded in 1984, CSG provides energy savings strategies, program design, management services/brand technologies to utilities, government agencies, energy services companies, public housing/brauthorities and other groups.

Mike O'Reilly

Mike O'Reilly is a Chesterfield, MO-based company in the Business Services sector.

Cellerant

Cellerant Therapeutics is a clinical stage biotechnology company focused on developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant`s programs include: CLT-008, an off-the-shelf cellular immunotherapy, under evaluation in a multicenter, open-label, randomized, controlled Phase 2 clinical trial in patients with de novo AML; CSC030-ADC, a preclinical monoclonal antibody drug conjugate that selectively targets and kills leukemic stem and blast cells responsible for initiating and maintaining disease; and CSC012, a preclinical monoclonal antibody targeting leukemic and pre-leukemic stem cells for acute leukemias and myelodysplastic syndromes. The Company is also developing next generation CAR product candidates leveraging its proprietary immunocellular therapy and antibody discovery and development platform.